Advertisement

Topics

Caris Diagnostics Company Profile

14:07 EST 20th November 2017 | BioPortfolio

Caris Diagnostics (Caris Dx) is a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing. Caris Diagnostics provides world-class pathology services to physicians who treat patients in the community setting. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowship and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Diagnostics provides the highest levels of service to its customers and their patients through its state-of- the-art laboratories; proprietary, advanced clinical and technology solutions; and rigorous quality assurance programs. Through the molecular testing expertise of the Caris Molecular Profiling Institute (Caris MPI) at Caris Dx, the company also offers advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to provide critical information to physicians treating cancer and other complex diseases. In addition, Caris MPI supports pharmaceutical companies and other researchers in their clinical trials for targeted therapeutics with custom genomic and proteomic analyses, analyte preservation, tissue procurement and comprehensive reporting services. The company has strategic relationships with the International Genomics Consortium, US Oncology, the Translational Genomics Research Institute, and the Biodesign Institute of Arizona State University. More than 2,000 physicians nationally use Caris Diagnostics. Formed in 1996, the company is headquartered in Irving, Texas and operates four laboratories: Irving, Texas; Phoenix, Arizona (2 sites); Newton, Massachusetts. Additional information is available at http://www.carisdx.com.


News Articles [510 Associated News Articles listed on BioPortfolio]

Caris Life Sciences Files Patent Infringement Suit against Foundation Medicine, Inc.

According to the complaint, Foundation Medicine infringes five U.S. Patents (Nos. 8,880,350; 9,372,193; 9,383,365; 9,092,392; and 9,292,660) held by Caris. The patents cover Caris' novel Read more...

Caris Life Sciences Files Patent Infringement Suit vs. Foundation Medicine

Caris Life Sciences has sued Foundation Medicine in federal court, accusing the company of infringing on five Caris patents in the development of its cancer assays FoundationOne ® , FoundationACT...

The St. Jude Crosson Cancer Institute Joins The Precision Oncology Alliance Powered By Caris Life Sciences

IRVING, Texas, Oct. 11, 2017 /PRNewswire/ -- Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that St. Jude M...

Caris’ studies show use of molecular profiling to develop oncology therapies

US-based Caris Life Sciences has reported positive data from two studies conducted for the validation of its tumour molecular profiling approach to guide the development of therapeutic strategies.

The St. Jude Crosson Cancer Institute Joins the Precision Oncology Alliance Powered by Caris Life Sciences

IRVING, Texas , Oct. 11, 2017 /- Caris Life Sciences ® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that St. Jude Medica...

John Wayne Cancer Institute joins Caris' Precision Oncology Alliance

Co-Diagnostics, Synbiotics launch joint venture CoSara Diagnostics in India

Co-Diagnostics, a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, officially announced the recent incorporation of CoSara Diagnostics, a ...

IPO nets $6.4mm for Co-Diagnostics

Molecular diagnostics start-up Co-Diagnostics Inc. netted $6.4mm through its initial public offering of 1.18mm common shares at $6 each on the Nasdaq.

Drugs and Medications [20 Associated Drugs and Medications listed on BioPortfolio]

Oxygen [A.M. Home Diagnostics Inc. dba Healthline]

Oxygen

Cystografin dilute diatrizoate meglumine injection usp 18% [Bracco Diagnostics Inc.]

CYSTOGRAFIN DILUTE Diatrizoate Meglumine Injection USP 18%

Cystografin diatrizoate meglumine injection usp 30% [Bracco Diagnostics Inc.]

CYSTOGRAFIN Diatrizoate Meglumine Injection USP 30%

Multihance [Bracco Diagnostics Inc]

These highlights do not include all the information needed to use MultiHance safely and effectively. See full prescribing information for MultiHance. MultiHance (gadobenate dimeglumine) injection Init...

Reno-30 diatrizoate meglumine injection usp 30% [Bracco Diagnostics Inc.]

RENO-30 Diatrizoate Meglumine Injection USP 30%

PubMed Articles [220 Associated PubMed Articles listed on BioPortfolio]

Component resolved diagnostics for hymenoptera venom allergy.

Component-resolved diagnostics makes use of defined allergen molecules to analyse IgE-mediated sensitizations at a molecular level. Here, we review recent studies on the use of component-resolved diag...

Comprehensive genetic study of cystic fibrosis in Slovak patients in 25 years of genetic diagnostics.

Cystic fibrosis (CF) has one of the longest histories in hereditary disease molecular diagnostics. However, identification of causative mutations in the CFTR gene is complicated by over two thousand c...

Advances in point-of-care technologies for molecular diagnostics.

Advances in miniaturization, nanotechnology, and microfluidics, along with developments in cloud-connected point-of-care (POC) diagnostics technologies are pushing the frontiers of POC devices toward ...

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.

Deficient mismatch repair (MMR) and microsatellite instability (MSI) contribute to ~15% of colorectal cancer (CRCs). We hypothesized MSI leads to mutations in DNA repair proteins including BRCA2 and c...

Local enamel demineralization diagnostics and treatment.

The article describes focal enamel demineralization - the most common disease of teeth hard tissues. Local and general factors of this pathological process advent and development were described. The m...

Clinical Trials [167 Associated Clinical Trials listed on BioPortfolio]

POA Prospective Repository

This repository is a multi-center, outcomes study designed to collect data on the demographics, presentation, diagnosis, treatment, cost of associated care, quality of life, and outcomes o...

Caris Molecular Intelligence Registry

This data collection Registry is a multi-center, observational outcomes Database designed to collect data on the demographics, presentation, diagnosis, treatment, resource use, quality of ...

POA Retrospective Repository

This repository is a multi-center, outcomes study designed to retrospectively collect data on the demographics, presentation, diagnosis, treatment, cost of associated care, quality of life...

LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer

This is a pilot feasibility study assessing the use of a commercial molecular profiling service in the UK's National Health Service (NHS). The impact of knowledge of a patient's molecular ...

Differential Diagnostics of Etiology of Acute Infections

Method for diagnostics of the origin of infections (bacterial vs viral) based on the identification of activation markers of blood neutrophils and monocytes will be developed.

Companies [898 Associated Companies listed on BioPortfolio]

CDX Holdings

CDX Holdings is the parent company of Caris Diagnostics and Caris Molecular Diagnostics, whose principal subsidiary is Caris MPI. Through its subsidiaries, CDX Holdings is a leading provider of th...

Caris Diagnostics

Caris Diagnostics (Caris Dx) is a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing. C...

Sekisui Diagnostics

A Sekisui Chemical company since 2011, Sekisui Diagnostics is a leading supplier of high quality products to diagnostic manufacturers, clinical laboratories and physician offices ...

Innotrac Diagnostics Oy

Founded 1995Located in Turku, FinlandInnotrac Diagnostics provides health care professionals with a comprehensive immunoassay platform and test portfolio for rapid and high quality results in cardiac ...

Cleveland Diagnostics, Inc.

Cleveland Diagnostics, Inc., is a clinical-stage biotechnology company developing technology to improve cancer diagnostics. Its Solvent Interaction Analysis (SIA) technology inves...

More Information about "Caris Diagnostics" on BioPortfolio

We have published hundreds of Caris Diagnostics news stories on BioPortfolio along with dozens of Caris Diagnostics Clinical Trials and PubMed Articles about Caris Diagnostics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Caris Diagnostics Companies in our database. You can also find out about relevant Caris Diagnostics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...


Corporate Database Quicklinks



Searches Linking to this Company Record